Information Provided By:
Fly News Breaks for November 15, 2019
Nov 15, 2019 | 07:23 EDT
H.C. Wainwright analyst Yi Chen lowered his price target for Ocular Therapeutix to $6 from $9 and reiterates a Buy rating on the shares following the company's Q3 results. The analyst believes Dextenza could have growing market adoption going forward, but says his revenue projections for 2020 and beyond could be too optimistic. He lowered his 2020 revenue projection to $26.5M from $52.0M.
News For OCUL From the Last 2 Days
There are no results for your query OCUL